Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma

Keyphrases

• Phase II Study 100%
• Recombinant interleukin-2 100%
• Levamisole 100%
• Advanced Malignant Melanoma 100%
• Interleukin-2 50%
• Nineteen 25%
• Antineoplastic Agents 25%
• Therapeutic Effectiveness 25%
• Activated Cells 25%
• Phase I Trial 25%
• Lethargy 25%
• Phase II Trial 25%
• Tumor Regression 25%
• Immune Stimulation 25%
• Vomiting 25%
• Adoptive Immunotherapy 25%
• Lymphokine-activated Killer Cells 25%
• Median Time 25%
• Complete Regression 25%
• Advanced Cancer 25%
• Partial Regression 25%
• Time to Treatment Failure 25%

Nursing and Health Professions

• Recombinant Interleukin 2 100%
• Levamisole 100%
• Melanoma 100%
• Interleukin 2 50%
• Treatment Failure 25%
• Central Stimulant Agent 25%
• Advanced Cancer 25%
• Tumor Regression 25%
• Lymphokine 25%
• Adoptive Immunotherapy 25%
• Time to Treatment 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Recombinant Interleukin 2 100%
• Levamisole 100%
• Interleukin 2 50%
• Tumor Regression 25%
• Lymphokine 25%
• Immunotherapy 25%
• Phase I Trials 25%
• Advanced Cancer 25%
• Phase II Trials 25%